Jessica R. Rosenstock and Scott Biest
Osteoporosis
GENERAL PRINCIPLES
· Peak bone mineral density (BMD) is attained by 19 years of age and is determined primarily by genetic factors.1
· Osteoporosis can have serious consequences on quality of life:
o Possible manifestations include pain, permanent disfigurement, loss of height, loss of self-esteem, and increased risk of hip fracture.
o Only one-third of patients who experience a hip fracture are able to return to their prefracture level of function.
o Half of all women who have a hip fracture spend time in a nursing home.
o The 1-year mortality after a hip fracture has been reported to be as high as 27%, although recent data indicate this rate may be decreasing.2,3
· Osteoporosis is clinically silent until the first fracture occurs; therefore, it is imperative that those at risk for this disease are identified early and that steps are taken to prevent bone loss and fracture.
Definition
Osteoporosis is defined as a disease of low bone mass and microarchitectural deterioration of bone tissue that leads to enhanced bone fragility and a consequent increase in fracture risk.4
Risk Factors
· Low bone mass is the single most accurate predictor of fracture.
· Risk factors for low bone density (Table 3-1) have limited value in estimating a woman’s actual bone density.5
· Risk factors for fracture that are independent of BMD are presented in Table 3-1.
· Significant ethnic variation exists: BMD is highest in African American women, lower in Mexican American women, and lowest in Caucasian women.6
· Ten-year fracture risk can be estimated using the World Health Organization (WHO) Fracture Risk Assessment Tool (FRAX) available at http://www.shef.ac.uk/FRAX (last accessed 2/20/14).7
TABLE 3-1 Risk Factors for an Osteoporotic Fracture or Low Bone Density
DIAGNOSIS
Clinical Presentation
History
· Risk factor screening is a useful tool in the evaluation of patients with osteoporosis, as it allows the physician to recognize factors that can influence bone density and fracture risk (Table 3-1).
· Essential historical information includes the following:
· Height at age 30 years and any loss of height
· Medications, including heparin, thyroid medications, diuretics, hormone replacement/oral contraceptive pills (OCPs), phenytoin/phenobarbital, prednisone, calcium, calcitonin, vitamins, raloxifene, or bisphosphonates
· Dietary history, specifically calcium intake
· Fractures or falls as an adult
· Family history of fractures or osteoporosis
· Physical activity
· Menstrual history
· Pain and functional limitations of activities of daily living
Physical Examination
· A complete physical examination should be performed on each patient, with emphasis on accurate measurement of height and weight.
· A spinal examination should be included, noting evidence of kyphosis, pain, and muscle spasm.
· Gait stability and fall risk should be assessed including balance, proprioception, and muscle strength.
Diagnostic Testing
Laboratories
· Laboratory studies should be limited and directed by the history and physical examination.
· Fractures in relatively young postmenopausal women or those with BMD lower than expected for her age may necessitate a workup for secondary causes of osteoporosis.8
· Comprehensive biochemical profile provides a simple screen for secondary causes, such as calcium-phosphorus ratio for hyperparathyroidism, total protein-albumin ratio for myeloma, and screening for liver and kidney disease.
· Thyroid-stimulating hormone (TSH) should be measured in patients with symptoms of thyroid dysfunction or those who are receiving thyroid replacement.
· 25-Hydroxyvitamin D screens for body stores of vitamin D (desirable ≥30 ng/mL).
· Additional studies can be considered for those with very low bone mass or those who continue to lose bone despite antiresorptive therapy. These studies include parathyroid hormone (PTH) battery, 24-hour urine for calcium excretion, serum protein electrophoresis (SPEP), cortisol levels, estradiol levels in women, testosterone levels in men, screening for celiac disease, and bone biopsy (rarely required).
Imaging
· Bone densitometry has improved the diagnosis and treatment of osteoporosis. It allows the clinician to diagnose low bone mass before a fracture occurs. Bone mass measurement is an accurate predictor of fractures.9
· The indications for bone mineral densitometry according to the Bone Mass Measurement Act of 1998 are presented in Table 3-2 and those of the National Osteoporosis Foundation (NOF) in Table 3-3.10
TABLE 3-2 Indications for Bone Mineral Densitometry, Bone Mass Measurement Act of 1998
TABLE 3-3 National Osteoporosis Foundation Indications for Bone Mineral Density Testing
· All bone mass measurement techniques are valuable for making the diagnosis of osteoporosis and predicting fracture risk.
· The most widely available methods are single x-ray absorptiometry, dual x-ray absorptiometry (DXA), quantitative computed tomography, and ultrasound densitometry.
· Techniques vary in terms of precision, cost, radiation exposure, and ability to follow changes over time.
· The most common method of measuring bone mass and currently the gold standard is DXA.
· For the diagnosis of osteoporosis, the bone density of a patient is compared with the mean young adult normal reference range (the T score).
· The WHO has developed diagnostic criteria for osteoporosis using T scores (Table 3-4)11:
TABLE 3-4 World Health Organization Criteria for the Diagnosis of Osteoporosis
Diagnostic guidelines developed for postmenopausal women.SD, standard deviation.
· A T score of −2.5 (2.5 standard deviations below the young-adult mean BMD) is defined as osteoporosis because more than half of osteoporotic fractures occur below that level.
· Z scores, which compare a patient’s BMD with that of age-matched controls, are also reported on bone mass measurement.
· If the Z score is more than two standard deviations below age-matched subjects, a cause other than age-related bone loss should be considered, and a secondary cause of osteoporosis should be sought.
· Serial BMD measurements can be used to monitor the effect of treatment or the clinical course of a specific medical condition.
· The usefulness of serial measurements is dependent on the precision error of the measuring device used.
TREATMENT
Medications
· Regardless of the specific therapy for the prevention or treatment of osteoporosis, all patients should receive adequate calcium and vitamin D, engage in regular weight-bearing exercise, and stop smoking.
· According to the NOF, treatment should be strongly considered in postmenopausal women and men aged 50 years or older with the following9:
· Hip or vertebral fracture
· T score of ≤ −2.5 at the femoral neck or spine (after appropriate evaluation to exclude secondary causes)
· Low BMD (T score of −1.0 to −2.5 at the femoral neck or spine) and a 10-year risk of hip fracture of ≥3% or a 10-year risk of any major osteoporotic fracture of ≥20% (based on the WHO FRAX algorithm, http://www.shef.ac.uk/FRAX, last accessed 2/20/14)
First Line
· Bisphosphonates
· For most patients, bisphosphonates are first-line therapy. All increase the BMD and reduce the risk of fractures.
· Bisphosphonates inhibit the action of osteoclasts.
· The bisphosphonates alendronate, risedronate, ibandronate, and zoledronic acid are approved for the prevention and treatment of osteoporosis.
· Orally administered bisphosphonates are poorly absorbed and therefore, should be taken first thing in the morning, on an empty stomach, with no liquid, food, or other medications taken for at least 30 minutes. Calcium supplements should not be taken for at least 1 hour afterwards.
· When taken orally, bisphosphonates may cause esophagitis. Therefore, patients should sit or stand for at least 30 minutes after taking the drug with at least 8 oz of water. If taken properly, tolerance is excellent.12 Less frequent administration may also improve gastrointestinal tolerability.13
· There may also be a link between the administration of bisphosphonates and osteonecrosis (avascular necrosis) of the jaw. The level of risk is not precisely known but is most likely very small. Risk factors appear to be high-dose IV administration, cancer, and dental procedures.14–18
· IV administration can result in flu-like symptoms (fever, arthralgias, myalgias, and headache) and transient hypocalcemia. The latter underscores the importance of calcium and vitamin D supplementation.
· The maximal duration of bisphosphonate therapy is uncertain. However, some recommend discontinuation of therapy or a drug holiday after 5 years.
· An increasing or stable BMD (generally measured every 2 years) is indicative of a positive treatment effect.
· Alendronate
o Alendronate has been shown to improve BMD in the spine by 8.8% and in the hip by 5.9% after 3 years of therapy.19 A meta-analysis of 11 randomized trials found after 3 years of ≥10 mg of alendronate, a 7.48% increase in BMD of the lumbar spine and 5.60% of the hip.20
o Women with osteoporosis treated with alendronate therapy for 3 years (2 years of 5 mg and 1 year of 10 mg) had a reduction in vertebral fractures by 47% and hip fractures by 51%.21 The above-mentioned meta-analysis found a pooled relative risk (RR) of fracture of 0.52 for vertebral fractures and 0.51 for nonvertebral fractures.20
o The recommended dosage for the treatment of osteoporosis in men and women is alendronate, 10 mg PO daily or 70 mg PO once weekly.22
o The dosage for the prevention of osteoporosis in postmenopausal women is 5 mg/day or 35 mg once weekly.
o The dose for the treatment of corticosteroid-induced osteoporosis is 5 mg/day, except in postmenopausal women not receiving estrogen, for whom the recommended dosage is 10 mg/day.
· Risedronate
o Risedronate has been shown to improve BMD in the spine by 4% to 6% and in the hip by 1% to 3%.23
o The Vertebral Efficacy with Risedronate Trial (VERT) showed a 41% to 49% reduction in spinal fractures and a 39% reduction in nonvertebral fractures.23,24 Women aged 70 to 79 years with confirmed osteoporosis had a 40% reduction in hip fractures with 5 mg/day.25
o A meta-analysis of eight randomized trials found, after at least 1 year of 5 mg risedronate, an increase in BMD of 4.54% for the lumbar spine and 2.75% for the femoral neck. The RR of fracture after at least 1 year of ≥2.5 mg of risedronate was 0.64 for vertebral fractures and 0.73 for nonvertebral fractures.26
o Recommended dosage for treatment and prevention of postmenopausal osteoporosis is risedronate, 5 mg PO daily. The dose for the prevention and treatment of corticosteroid-induced osteoporosis is 5 mg/day, or 35 mg once weekly,27 or 75 mg on 2 consecutive days a month,28 or 150 mg once monthly.29
· Ibandronate
o Ibandronate daily or intermittently has also been shown to significantly increase BMD and decrease fractures.30–33
o The recommended dosage of ibandronate is 150 mg monthly.34,35
o Ibandronate can also be administered IV, 3 mg every 3 months.36,37 This regimen may be effective for those who cannot tolerate oral administration or who cannot follow oral dosing precautions.
· Zoledronic Acid
o IV zoledronic acid is approved for the treatment and prevention of osteoporosis.
o Both once-yearly and intermittent administration increase BMD38 and reduce the risk of vertebral (70%) and hip fractures (41%).39
o If given within 90 days after repair of a hip fracture, zoledronic acid reduces the risk of new fractures (35%) and improves survival (28%).40
o The recommended dosage for treatment of osteoporosis is 5 mg IV over at least 15 minutes annually. For prevention of osteoporosis, the recommended dose is 5 mg IV every 2 years.
o Zoledronic acid also has indications for hypercalcemia of malignancy, multiple myeloma, and bone metastases from solid tumors.
· Raloxifene
· Raloxifene is a selective estrogen receptor (ER) modulator. It inhibits the loss of BMD but does not cause endometrial hyperplasia.
· In the Multiple Outcomes of Raloxifene Evaluation (MORE) trial, 7,705 women were assigned to receive placebo or raloxifene at 60 or 120 mg. Treatment with raloxifene increased the BMD of the femoral neck and spine by 2.1% to 2.3% and 2.5% to 2.6%, respectively, compared with placebo.41,42 During the 4-year continuation of a subset of MORE subjects (Continuing Outcome Relevant to Evista, CORE), differences in BMD between raloxifene and placebo were maintained.43
· Vertebral fractures were reduced by 30% to 50%.41,42,44
· No data support reduction in nonvertebral fractures at this time.41–44
· The MORE trial revealed a 70% reduction in the development of invasive breast cancer in patients who were treated with raloxifene and had no effect on the endometrium.45 The Raloxifene Use for The Heart (RUTH) trial demonstrated a 43% reduction in invasive breast cancer.46 During the combined MORE/CORE 8 years, there was a 66% reduction in invasive breast cancer and a 76% reduction in ER-positive invasive breast cancer.47 There was no change in the incidence of ER-negative invasive breast cancer.
· Total serum cholesterol and low-density lipoprotein cholesterol levels decreased significantly without change in high-density lipoprotein or triglyceride levels. Raloxifene 60 mg daily reduced the total cholesterol level by 6.4% and the low-density lipoprotein level by 10.1%.48
· Raloxifene does not appear to have a significant effect on the risk of coronary events.46,49
· The risk of venous thromboembolism with raloxifene may be elevated: MORE trial RR 2.1 to 3.1, CORE study RR 2.17, and RUTH trial hazard ratio (HR) 1.44.41,46,47,49,50 The risk is probably less than that seen with tamoxifen.51
· In the RUTH trial, raloxifene was associated with an increased risk of fatal stroke (HR 1.49) but not with total stroke or all-cause mortality.46
· Other side effects include hot flashes and leg cramps.
· The recommended dosage of raloxifene for prevention and treatment is 60 mg daily.
· Calcitonin
· Salmon or human calcitonin can be given as an SC injection or as a nasal spray.
· BMD increases by 1% to 2% in patients who are treated with 200 IU calcitonin nasal spray daily.
· The Prevent Recurrence of Osteoporotic Fracture (PROOF) trial showed a reduction in vertebral fractures by 36% with the nasal spray in women who were 5 years postmenopausal with vertebral fractures. However, 59% of participants withdrew prematurely; therefore, results of this study should be interpreted cautiously. No significant reduction in hip fractures occurred.52
· A meta-analysis showed a reduction in vertebral fractures (RR 0.46) and nonvertebral fractures (RR 0.52).53
· Most consider calcitonin less effective than bisphosphonates.
· Calcitonin has an analgesic effect when given as treatment for compression fractures.54
· Recommended dosage for the treatment of women >5 years postmenopausal with low bone mass is one spray (200 IU) in one nostril daily. The patient should alternate nostrils each day. The SC dose is 100 IU/day.
· Parathyroid Hormone
· PTH is considered to be an “anabolic” treatment, in that it stimulates bone formation rather than acting as an antiresorptive.
· Intermittent PTH administration, as opposed to chronic elevations (as seen with chronic kidney disease or primary hyperparathyroidism), stimulates the maturation of osteoblasts and, therefore, bone formation. The explanation for this incongruity is not fully understood.
· PTH affects trabecular bone more than cortical bone and qualitatively improves trabecular architecture.
· PTH is usually given as recombinant human PTH amino acids 1 to 34, known as teriparatide. Intact PTH is also effective.55
· In the Fracture Prevention Trial (FPT) of 1,637 postmenopausal women with a prior vertebral fracture randomized to placebo or 20 or 40 μg teriparatide daily, BMD increased in the spine and hip but not in the radial shaft.56
· After a median treatment period of 21 months in the FPT, there was significant reduction in vertebral fractures (RR 0.31 to 0.35) and nonvertebral fractures (RR 0.46 to 0.47).56 BMD increases before fracture reduction occurs.
· Side effects include hypercalcemia, nausea, headache, leg cramps, and dizziness.
· Animal studies suggest an increased risk of osteosarcoma. Teriparatide should not be given to patients with existing risk factors for osteosarcoma such as Paget disease, skeletal radiation therapy, or a history of bone malignancy.
· The recommended dosage of teriparatide is 20 μg subcutaneously daily for a maximum of 2 years.
· A bisphosphonate is typically given after completion of teriparatide.57 However, concurrent administration of alendronate does not produce an additive effect and may actually reduce the effects of PTH.58
· Estrogen Replacement Therapy (ERT)
· Estrogen therapy (ET) has been shown to slow down bone loss following menopause or to increase it by as much as 6%.59
· Since the publication of the Women’s Health Initiative (WHI) findings (excess coronary events, strokes, pulmonary emboli, and invasive breast cancer) and the availability of other effective drugs, ET is no longer considered appropriate for first-line therapy for the prevention and treatment of osteoporosis.60
· Dosing is discussed in the “Menopause” section below.
· Denosumab
· Denosumab is a human monoclonal antibody to receptor activator of nuclear factor kappaB ligand (RANKL), an osteoclast differentiating factor. It inhibits osteoclast formation, thereby decreasing bone resorption and increasing BMD.
· Denosumab is approved for treatment of osteoporosis in postmenopausal women at high risk of fracture.
· In the FREEDOM Trial, 7,868 women aged 60 to 90 with osteoporosis were randomly assigned denosumab or placebo every 6 months for 36 months. Denosumab reduced the risk of vertebral fracture by 68%, the risk of hip fracture by 40%, and the risk of nonvertebral fracture by 20%.61
· Recommended dosing is 60 mg subcutaneously every 6 months.
Lifestyle/Risk Modification
Smoking cessation and alcohol intake reduction are important for those with or at risk for osteoporosis.
Diet
· Diet therapy is essential in the prevention and treatment of osteoporosis.
· Calcium supplementation alone has a small positive effect on BMD.62
· Calcium intake for postmenopausal women should be 1,200 mg/day.
· Examples of the elemental calcium content of various foods include the following: 8-oz glass of milk contains 300 mg, 1 oz of Swiss cheese contains 270 mg, and 1 cup of cooked broccoli contains 100 mg.63
· Eating calcium-fortified foods should be encouraged.
· Calcium supplements: Calcium carbonate is acceptable for most patients. It is cheap and has relatively few side effects. Guidelines for calcium supplementation:
· Calcium is best absorbed in small amounts; consider dividing the daily dose if >500 mg.
· Synthetic calcium supplements are optimal. Oyster shell calcium, dolomite, and bone meal can contain heavy metal contaminants.64
· Vitamin D (800 to 1,000 IU PO daily) is beneficial for patients with osteoporosis. Ambulatory men and women older than the age of 65 years who were given calcium carbonate and vitamin D had a significant reduction in nonvertebral fractures.65 Patients with significant hypovitaminosis D require more aggressive repletion.
Activity
Exercise, including weight-bearing and muscle-strengthening exercise, should be encouraged in patients with osteoporosis as allowed by their functional status.
SPECIAL CONSIDERATIONS
Management of Corticosteroid-Induced Osteoporosis
· Skeletal effects of corticosteroids include decreased BMD and increased fracture risk and are related to dose and duration of therapy.
· Daily prednisone doses of ≥7.5 mg/day can result in significant bone loss. Lower doses can also have an effect on bone metabolism. Alternate-day regimens have not been shown to be superior.
· Bone densitometry should be considered for any patient who is presently receiving corticosteroids or if long-term therapy is initiated.
· Patients who are on corticosteroids should maintain adequate calcium (1,500 mg/day) and vitamin D (800 IU) intake.
· Weight-bearing exercise should be encouraged.
· Alendronate has been shown to prevent bone loss in patients receiving corticosteroids and to reduce the risk of fractures in postmenopausal women on corticosteroids.66,67
· Risedronate and zoledronic acid are similarly effective.68–71
· Calcitonin may preserve bone loss, but it has not been shown to prevent fractures in the setting of corticosteroid treatment.72,73
· Teriparatide may be more effective than alendronate in patients who have osteoporosis and have received corticosteroids for at least 3 months.74
Management of Osteoporosis in Men
· If a male patient presents with a fracture that is associated with mild-to-moderate trauma, BMD testing should be performed, and a search for secondary causes of bone loss should be considered.
· Evaluation should look for risk factors for osteoporosis including drugs that could affect BMD, such as corticosteroids or anticonvulsants; history of alcohol ingestion (>100 g/day); or nicotine use.
· Appropriate laboratory studies should be done including SPEP, complete blood cell count, calcium, phosphate, albumin, creatinine, alkaline phosphatase, PTH battery, TSH, free testosterone, 25-hydroxyvitamin D, 24-hour urine collection for calcium and creatinine excretion, and cortisol levels.
· Causes of hypogonadism, such as Klinefelter syndrome, hyperprolactinemia, anorexia nervosa, and hemochromatosis, should also be considered. Bone biopsy may be needed if no etiology is found.
· As with female patients, sufficient calcium and vitamin D is important. Patients should be encouraged to stop smoking and drinking alcohol.
· If a secondary cause is found, it should be treated.
· Hypogonadism is a relatively common cause, and testosterone replacement increases BMD.75–77 Alendronate has been shown to maintain BMD and prevent fractures in men with osteoporosis, vertebral fracture (odds ratio [OR] 0.44) and nonvertebral fracture (OR 0.60).78
· Risedronate has been shown to reduce vertebral fractures and increase the bone mass in men treated with corticosteroids.79–82
· Teriparatide has also been shown to be effective in men.83–85
PATIENT EDUCATION
· Patient education is essential for the prevention and treatment of osteoporosis particularly with regard to fall prevention. Patients at risk should be instructed to:
o Look for and remove throw rugs, loose carpets, slippery floors, cords and wires, or anything that can cause a patient to slip.
o Inspect home for unstable furniture or clutter that can obstruct mobility.
o Ensure adequate lighting, especially at night.
o Have grab bars installed for the toilet and place a nonslip surface in the shower.
o Wear properly fitting shoes.
o Have irregular sidewalks and uneven surfaces repaired and have accumulated ice or snow removed.
· Correct vision and hearing problems.
· Eliminate causes of postural hypotension if possible. Otherwise, advise patients to get up slowly.
· Hip protectors may reduce hip fractures in nursing home patients.86,87 Acceptance of and adherence to hip protectors is relatively low.
Menopause
GENERAL PRINCIPLES
· The menopausal transition period is typified by variation in menstrual cycle length and eventual skipped periods.
· Menopause is the cessation of menstrual periods, defined retrospectively after 12 months of amenorrhea.
· The average age of menopause is 50 to 51 years.88
· With ovarian failure, follicle-stimulating hormone and luteinizing hormone levels rise and estradiol levels fall.
· Other causes of amenorrhea and menopausal symptoms should be considered including excessive weight loss, concurrent medical illnesses, pregnancy, thyroid disease, pituitary disease, and medications.
DIAGNOSIS
Clinical Presentation
· Symptoms associated with menopause include the following:
o Irregular bleeding
o Hot flashes/night sweats
o Sleep disturbance
o Vaginal dryness/itching/dyspareunia
o Sexual dysfunction
o Urinary incontinence
o Mood changes (inconsistent degree of association)
· Menopausal symptoms typically last for a few months but can persist for several years.88
· Hot flashes affect approximately 75% of menopausal women. They occur most frequently at night and are due to estrogen deficiency. It is believed that estrogen withdrawal lowers the temperature set point in the hypothalamus to reduce the body thermostat. As a result, vasodilatation of the vessels in the hands and upper body occurs so that the heat in the central organs is lost at the periphery.89
o Hot flashes are not synonymous with estrogen deficiency.
o Other causes of hot flashes should be considered, such as pheochromocytoma, carcinoid, pregnancy, thyroid disease, and panic disorder.
· Long-term effects in the postmenopausal period include osteoporosis and increased cardiovascular disease risk.
Diagnostic Testing
· Diagnostic testing is generally unnecessary.
· As noted, follicle-stimulating hormone and luteinizing hormone levels are high and estradiol levels are low.
· Other tests may be indicated to rule out other possible causes of amenorrhea.
TREATMENT
· Hot flashes
o Estrogen therapy (ET)
§ ET is the most effective treatment.88,90,91
§ However, the results of the WHI and the Heart and Estrogen/progestin Replacement Study (HERS) have greatly called into question the advisability of long-term (i.e., greater than approximately 5 years) or chronic indefinite ET, specifically with regard to combined estrogen and progestin treatment.60,92 It is important to recognize that the direct applicability of these studies to all menopausal women is somewhat tenuous.93
o Quality of life is also a very important consideration.94
§ The balance of risks and benefits appears to be more favorable for women who have had a hysterectomy receiving estrogen-only treatment in comparison with women with a uterus receiving combined estrogen-progestin treatment.
§ On balance, short-term (i.e., less than approximately 2 to 3 years) administration of the lowest effective dose of estrogen is a viable option for women with moderate-to-severe vasomotor symptoms who have no history of cardiovascular disease, breast cancer, endometrial cancer, or venous thromboembolism.91,93,94
§ Low-dose estrogen therapies include 0.3 mg oral conjugated estrogen, 0.25 to 0.5 mg micronized 17β-estradiol, and 0.025 mg transdermal 17β-estradiol patch.93 Higher doses may be necessary in some patients for symptom control.
§ A progestin must be added in women with an intact uterus.95
§ Low-dose (i.e., containing 20 μg of ethinyl estradiol) OCPs are also a reasonable option for women less than approximately 50 years old.
§ ET can generally be tapered off gradually after a year or two. Some women may have recurrent hot flashes.
§ Other side effects of estrogen include abdominal bloating, cramps, breast tenderness, hypertriglyceridemia (oral estrogen only), breakthrough bleeding, weight changes, enlargement of benign tumors of the uterus, dry eyes, and skin changes.
§ Side effects of progestins include breakthrough bleeding, edema, weight changes, rash, insomnia, and somnolence.
o Other treatments
§ Simple environmental changes, including keeping the room cool and dressing in layers, may make hot flashes more tolerable.
§ Serotonin reuptake inhibitors (SSRIs, e.g., paroxetine and fluoxetine) and serotonin-norepinephrine reuptake inhibitors (SNRIs, e.g., venlafaxine) are effective for vasomotor symptoms but not as much as ET.88,91,96
§ Gabapentin appears to be effective at reducing the frequency of hot flashes.88,91,97 Doses up to 900 mg/day may be required. Common side effects of gabapentin include dizziness/unsteadiness and fatigue/somnolence.
§ Studies regarding clonidine are of fairly low quality and conflicting.88,96
§ The effectiveness of soy foods, soy extracts, red clover extracts, and black cohosh is questionable.88,91,96,98,99
· Genitourinary symptoms
o Vaginal atrophy presents with dyspareunia, vaginal dryness, itching, and irritation. Oral and vaginal estrogen is useful for symptoms associated with vaginal atrophy. Systemic effects of vaginal estrogen are probably quite low. Concomitant progestin therapy is not necessary for women with a uterus receiving topical vaginal estrogen.
o The terminal urethra is embryonically related to the vagina. As it becomes thinner, there is more risk of infection and incontinence. Dysuria without evidence of infection is due to the thinning of the epithelium, allowing urine in close contact with the sensory nerves. Also, the normal urethral pressures created by the urethra and surrounding tissues are decreased. Topical estrogen in some studies has been shown to reduce the incidence of urinary tract infections.88,100
Cervical Cancer Screening
· Widespread screening with cervical cytology has dramatically reduced the incidence of and mortality from cervical cancer over the last three decades. Half of the women in the United States with invasive cervical carcinoma have never had a Pap smear, and another 10% have not had a Pap smear in 5 years.101
· Risk factors for developing cervical cancer include cigarette smoking, multiple sexual partners, early onset of sexual activity, history of sexually transmitted infection, increasing parity, prolonged use of OCPs, immunocompromise, and HIV infection.102,103
· Human papillomavirus (HPV) is the causative agent in almost all cases of cervical cancer. There are 15 to 18 subtypes of HPV that are considered “high risk” for causing cervical cancer. HPV-16 and 18 account for approximately 70% of all cases.102
· Cervical cancer screening with the Pap smear is recommended for all women who have a cervix. The American Cancer Society (ACS), United States Preventative Services Task Force (USPSTF), American Society for Colposcopy and Cervical Pathology (ASCCP), and American College of Obstetrics and Gynecology (ACOG) recently updated their joint guidelines for cervical cancer screening.
· Screening should begin at 21 years regardless of sexual history.
· ACOG, ASCCP, USPSTF, and ACS recommend the following:
o For women aged 21 to 29, cervical cytology screening alone is recommended every 3 years.
o Women aged 30 to 65 and older with negative results on three consecutive cervical cytology tests may be screened with cervical cytology and HPV cotesting every 5 years. Cytology alone every 3 years is also acceptable.
o Women aged >65 years do not require screening after adequate negative prior screening results.
o Women with a history of CIN 2, CIN 3, or adenocarcinoma in situ should continue routine age-based screening for at least 20 years.
o Women who have undergone hysterectomy for benign indications with previous history of advanced cervical dysplasia do not require screening.102,104,105
· Cervical intraepithelial neoplasias are usually divided into categories based on cytologic grades. The Bethesda system is the currently recognized reporting system. Included in this system is the pathologist’s interpretation of the smear, including the presence of benign cellular changes, evidence of cellular atypia, or both. Infectious processes such as Trichomonas, Candida, Actinomyces, or cellular changes associated with herpes simplex virus are reported. Reactive (but benign) changes associated with inflammation, atrophy, radiation, or intrauterine contraceptive device are also reported. The four categories of squamous cell abnormalities are as follows:
o Atypical squamous cells (ASC): of undetermined significance (ASC-US) or cannot exclude HSIL (ASC-H)
o Low-grade squamous intraepithelial lesions (LSIL)
o High-grade squamous intraepithelial lesions (HSIL)
o Squamous cell carcinoma
· ASC of undetermined significance (ASC-US) are subjected to reflex HPV testing and are managed based on the presence or absence of high risk strains of HPV.
o Those with positive testing for high-risk HPV types should be referred for colposcopy.
o In those with negative testing, cytology should be repeated in 3 years.
· ASC but HSIL cannot be ruled out (ASC-H) should be evaluated with colposcopy.106
· LSIL should be further evaluated with colposcopy. In adolescents, however, repeat cytology at 12 months is recommended.106 HPV testing is an option for postmenopausal women.
· HSIL must be further evaluated with colposcopy.106
· Women with positive HPV testing and negative cytology can be followed with repeat cotesting in 12 months or immediate HPV genotype-specific testing for HPV 16 or HPV 16/18. If positive, colposcopy is indicated.102
· Glandular cell abnormalities are another category of abnormal Pap smear results. These patients also require evaluation with colposcopy and endometrial biopsy if they are over age 35 or have risk factors for endometrial pathology such as obesity.
· HPV vaccination is recommended for all women aged 9 to 26 for primary prevention of cervical cancer.
Nipple Discharge
GENERAL PRINCIPLES
· Nipple discharge is common and mostly benign.
· Nipple discharge can be classified as lactation, physiologic (galactorrhea), or pathologic.
· Galactorrhea is bilateral, milky, involves multiple ducts, and occurs at least 1 year following cessation of breast-feeding or pregnancy.
o It is most commonly caused by hyperprolactinemia, also suggested by the presence of amenorrhea. Hyperprolactinemia may result from medications, pituitary tumors, or endocrine abnormalities.
o Hypothyroidism, chronic nipple stimulation, and renal insufficiency are less common causes of galactorrhea.107
o Medications associated with galactorrhea include antipsychotics, methyldopa, reserpine, Reglan, cimetidine, opioids, and antidepressants.107–109
· Pathologic nipple discharge is usually unilateral and localized to a single duct. It is spontaneous, intermittent, and persistent.
· The fluid can be serosanguineous, bloody, green, or clear.
· The most common cause of unilateral discharge is intraductal papilloma, followed by mammary duct ectasia.108
· About 10% to 15% of cases are due to breast carcinoma.108
· Purulent discharge can be caused by mastitis.
DIAGNOSIS
Clinical Presentation
· The history should include evaluation of menstrual pattern, recent pregnancy, infertility, medications, symptoms of hypothyroidism, breast stimulation or trauma, and presence of headaches or visual complaints.
· Medications associated with galactorrhea should be stopped, and pregnancy should be ruled out.
· Physical examination should include a complete breast examination and evaluation for signs of hypothyroidism or pituitary tumor.
· Try to determine if the discharge is from one or multiple ducts.
Diagnostic Testing
· If fluid is expressed and not grossly bloody, it should be evaluated for occult blood.
· Measurement of TSH, prolactin, creatinine, and a pregnancy test are indicated with discharge from multiple ducts.
· Mammography should be obtained in patients over 30 years of age with pathologic discharge. All patients should undergo periareolar ultrasound.
· Ductography, cannulation of the secreting duct followed by injection of contrast material, can be considered, but it is painful for patients and the technique is difficult. It has been reported to miss as many as 20% of ductal lesions.
· Magnetic resonance imaging and ductoscopy are also available diagnostic tests.
· Duct excision is indicated if abnormalities are identified on the above tests.109
TREATMENT
· Galactorrhea:
o Patients with normal periods and normal prolactin levels do not require treatment.
o Breast stimulation is discouraged.
o If the patient is receiving a medication that is associated with galactorrhea, the dose can be decreased or the drug stopped and the patient followed.
o The management of prolactinoma is discussed in Chapter 21.
· Patients with pathologic discharge should be referred for evaluation by a surgeon who is experienced with diseases of the breast for possible surgical intervention.
Breast Masses
GENERAL PRINCIPLES
Risk factors for breast cancer include female gender, increasing age, first-degree relative (mother or sister) with breast cancer (highest risk is if the relative was premenopausal and the cancer was bilateral), previous breast cancer, late age of first pregnancy, and nulliparity.
DIAGNOSIS
Clinical Presentation
History
· The patient should be questioned regarding any associated symptoms, such as pain and nipple discharge.
· Menstrual history should be obtained, as well as assessment of the possibility of pregnancy.
· Medications should be reviewed, and any history of trauma should be obtained.
· An accurate family history should be elicited. If a history of breast, ovarian, colon, or prostate cancer is found in numerous family members, genetic counseling should be considered.
Physical Examination
· Physical examination should include inspection and palpation of the breast with the patient seated and then lying flat. The breasts should be observed for skin dimpling or changes in contour.
· The breast should be palpated gently and circumferentially to the axilla, including the nipple, areola, and breast tissue.
· The nipple should be closely evaluated for discharge, and the character of the discharge should be noted. A ductal carcinoma may present with an isolated spontaneous serosanguineous discharge.
· The axillary and supraclavicular area should be palpated for evidence of a mass or enlarged lymph nodes.
Differential Diagnosis
· Differential diagnosis for a discrete nodule includes fibroadenoma, cyst, fibrocystic changes, malignancy, and trauma.
· A dominant nodule remains unchanged throughout the menstrual cycle.
· In fibrocystic disease, the palpable nodules frequently feel cystic and are subject to change during the menstrual cycle.
· Benign nodules have characteristics such as easy mobility, regular borders, and a soft or cystic feel. However, physical examination alone cannot exclude malignancy; therefore, other diagnostic tests are indicated.
TREATMENT
· Women younger than 30 years with a breast mass and no other symptoms can be observed through one menstrual cycle, and if it resolves, no further treatment is indicated. If the mass persists, ultrasound is a reasonable next step.
· Women over 30 years old should have a mammogram. Ultrasound may also be indicated.
· Routine screening mammography recommendations are discussed in Chapter 5.
VAGINITIS
· The presence of vaginal discharge is not always abnormal.
· Symptoms are usually nonspecific.
· The vagina has 25 bacterial species, and pH is usually 4.0 due to lactobacilli; however, semen, menses, and ectropion may alter the pH.
· Fifty percent of vaginitis is from bacterial vaginosis (BV), 25% from Trichomonas vaginitis, and 25% from Candida vaginitis.
· Management of sexually transmitted infections is discussed in Chapter 27.
Bacterial Vaginosis
GENERAL PRINCIPLES
· BV is thought to result from a polymicrobial alteration in the normal vaginal flora in which lactobacilli are replaced with high concentrations of anaerobes such as Gardnerella, Mycoplasma, and Prevotella.
· Gardnerella vaginalis may be cultured from 30% to 70% of healthy asymptomatic women.
· BV infection increases the risk of acquisition of some STIs (HIV, HSV-2, Neisseria gonorrhoeae, and Chlamydia trachomatis), gynecologic surgical complications, and pregnancy complications.110
DIAGNOSIS
· BV is characterized by malodorous vaginal discharge, with or without vaginal pruritus.
· The discharge is a homogeneous, nonviscous, grey-white fluid that coats the vagina and cervix.
· The presence of “clue cells” (epithelial cells with borders obscured by small bacteria) is an accepted criterion for diagnosis.
· The vaginal pH should be >4.5.
· Another common test (whiff test) involves the amine (fishy) odor released when the vaginal discharge is alkalinized by mixing with 10% KOH.
· No cultures are needed in clinical diagnosis of BV.
TREATMENT
· Treatment is recommended for symptomatic women.
· Metronidazole is the most effective antimicrobial for BV, with cure rates >90%.
o Standard treatment is metronidazole, 500 mg PO bid for 7 days.110
o Alternative treatments are metronidazole gel 0.75%, one application intravaginally every night for 5 nights or clindamycin cream 2%, one application intravaginally at night for 7 nights. Oral tinidazole or clindamycin are also alternatives.110
o Patients should be advised to avoid alcohol consumption during treatment with metronidazole due to a possible disulfiram-type reaction.
o Nausea and metallic taste are common side effects.111
· The effectiveness of probiotics is uncertain.112
· Relapses are relatively common after treatment.
Trichomonas Vaginitis
GENERAL PRINCIPLES
· Trichomonas vaginalis is a contagious protozoon that is acquired through sexual contact.
· It is often found in the presence of other sexually transmitted infections.
· Symptoms include diffuse, malodorous, yellow-green vaginal discharge, although many women are asymptomatic.
· T. vaginalis may also cause urethritis in men but is usually asymptomatic.
DIAGNOSIS
· Diagnosis can be made by microscopic detection of motile trichomonads on examination of a saline wet prep of vaginal or urethral secretions. The slide should be examined soon after preparation to detect motility. Organisms are detected in 60% to 70% of infected women.
· The vaginal pH should be >4.5, and whiff test may be positive.
· The “strawberry cervix” caused by cervical petechiae is a characteristic manifestation.
· The reliability of the Pap smear is quite variable.
· Culture is available but generally not necessary.
TREATMENT
· Standard treatment is single-dose metronidazole (2 g PO) or 500 mg PO bid for 7 days.110,113 Patients should be warned not to drink alcohol during the course of treatment.
· Tinidazole 2 g PO ×1 is an alternative therapy.
· The cure rate is approximately 90% to 95% with metronidazole and 86% to 100% with tinidazole.
· Most physicians advocate treating all patients who have detectable organisms to reduce the sexual transmission of the organism.
· Treatment of male sexual partners is recommended.110
Vulvovaginal Candidiasis
GENERAL PRINCIPLES
· This “yeast infection” is suggested by the presence of vulvovaginal soreness, dyspareunia, vulvar pruritus, external dysuria, and thick or “cheesy” vaginal secretions.
· It is typically caused by Candida albicans but can sometimes be caused by other Candida spp.
· Factors that predispose to colonization and infection include diabetes, steroid therapy, pregnancy, antibiotics, obesity, OCPs, immunosuppressant drugs, and HIV infection.
· Candidiasis is usually not transmitted sexually.
· Ten to twenty percent of women normally have yeast colonized in the vagina; 75% of women have at least one episode of Candida vaginitis, and 45% have two or more episodes during their lifetime.
DIAGNOSIS
· Speculum examination may reveal candidal plaques adherent to the vaginal mucosa with erythema or edema of the introitus.
· The vaginal pH is usually <4.5.
· Diagnosis can be made by inspection of the typical vaginal lesions or by observation of fungal elements (budding yeast and pseudohyphae) in a KOH preparation.
· Cultures may be obtained for symptomatic women with negative KOH testing.
· It is justifiable to treat an apparent or suspected candidal vulvovaginitis even with a negative KOH preparation (only 40% to 80% sensitive).
TREATMENT
· Treatment is with one of the imidazole antifungal drugs, such as butoconazole, clotrimazole, miconazole, terconazole, or tioconazole. All are more effective than is nystatin.110
o Courses of treatment range from single dose to 3 to 7 days depending on the agent and dose.
o Most agents come in cream or suppository for intravaginal use.
· If the woman is menstruating, she should not use tampons, which may absorb the drug.
· Single-dose oral fluconazole, 150 mg, is an effective alternative.
· Recurrent candidal infections are common and can be distressing. All predisposing factors should be addressed. Each recurrent episode generally responds to topical treatment, but longer treatment may be indicated. Oral fluconazole 100 to 200 mg every third day for 3 doses followed by maintenance suppression with fluconazole 100 to 200 mg weekly for 6 months may be effective.110,114
REFERENCES
1.Baxter-Jones AD, Faulkner RA, Forwood MR, et al. Bone mineral accrual from 8 to 30 years of age: an estimation of peak bone mass. J Bone Miner Res 2011;26:1729–1739.
2.Miller CW. Survival and ambulation following hip fracture. J Bone Joint Surg 1978;60:930–934.
3.Brauer CA, Coca-Perraillon M, Cutler DM, et al. Incidence and mortality of hip fractures in the United States. JAMA 2009;302(14):1573–1579.
4.Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646–650.
5.Slemenda CW, Hui SL, Longcope C, et al. Predictors of bone mass in perimenopausal women. A prospective study of clinical data using photon absorptiometry. Ann Intern Med 1990;112:96–101.
6.Looker AC, Melton LJ III, Harris TB, et al. Prevalence and trends in low femur bone density among older US adults: NHANES 2005-2006 compared with NHANES III. J Bone Miner Res 2010;25:64–71.
7.WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Geneva, Switzerland: World Health Organization, 2007.
8.American College of Obstetricians and Gynecologists Women’s Health Care Physicians. Osteoporosis. Obstet Gynecol 2012;129:718–734.
9.Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995;332:767–773.
10.Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008.
11.Kanis JA, Melton LJ III, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137–1141.
12.Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002;77:1031–1043.
13.Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 2007;30:755–763.
14.King AE, Umland EM. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 2008;28:667–677.
15.Pazianas M, Miller P, Blumentals WA, et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther2007;29:1548–1558.
16.Khan AA, Sándor GK, Dore E, et al.; Canadian Taskforce on Osteonecrosis of the Jaw. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009;36:478–490.
17.Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008;42:841–847.
18.Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753–761.
19.Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333: 1437–1443.
20.Cranney A, Wells G, Willan A, et al.; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23:508–516.
21.Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348:1535–1541.
22.Rizzoli R, Greenspan SL, Bone G III, et al.; Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res2002;17:1988–1996.
23.Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344–1352.
24.Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83–91.
25.McClung MR, Geusens P, Miller PD, et al.; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med2001;344:333–340.
26.Cranney A, Tugwell P, Adachi J, et al.; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:517–523.
27.Harris ST, Watts NB, Li Z, et al. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004;20:757–764.
28.Delmas PD, Benhamou CL, Man Z, et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int 2008;19:1039–1045.
29.Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008;42:36–42.
30.Delmas PD, Recker RR, Chesnut CH III, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int2004;15:792–798.
31.Chesnut CH III, Skag A, Christiansen C, et al.; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–1249.
32.Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin2008;24:237–245.
33.Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009;20:291–297.
34.Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315–1322.
35.Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654–661.
36.Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum2006;54:1838–1846.
37.Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008;35:488–497.
38.Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653–661.
39.Black DM, Delmas PD, Eastell R, et al.; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 20073;356(18):1809–1822.
40.Lyles KW, Colón-Emeric CS, Magaziner JS, et al.; HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799–1809.
41.Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–645.
42.Delmas PD, Ensrud KE, Adachi JD, et al.; Multiple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609–3617.
43.Siris ES, Harris ST, Eastell R, et al.; Continuing Outcomes Relevant to Evista (CORE) Investigators. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514–1524.
44.Cranney A, Tugwell P, Zytaruk N, et al.; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:524–528.
45.Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA1999;281:2189–2197.
46.Barrett-Connor E, Mosca L, Collins P, et al.; Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125–137.
47.Martino S, Cauley JA, Barrett-Connor E, et al.; CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751–1761.
48.Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med1997;337:1641–1647.
49.Collins P, Mosca L, Geiger MJ, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation 2009;119:922–930.
50.Grady D, Ettinger B, Moscarelli E, et al.; Multiple Outcomes of Raloxifene Evaluation Investigators. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol2004;104:837–844.
51.Vogel VG, Costantino JP, Wickerham DL, et al.; National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727–2741.
52.Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267–276.
53.Cranney A, Tugwell P, Zytaruk N, et al.; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:540–551.
54.Knopp JA, Diner BM, Blitz M, et al. Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 2005;16:1281–1290.
55.Greenspan SL, Bone HG, Ettinger MP, et al.; Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146:326–339.
56.Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–1441.
57.Black DM, Bilezikian JP, Ensrud KE, et al.; PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 2005;353:555–565.
58.Black DM, Greenspan SL, Ensrud KE, et al.; PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med2003;349:1207–1215.
59.Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996;276:1389–1396.
60.Rossouw JE, Anderson GL, Prentice RL, et al.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
61.Cummings SR, Sam Martin J, McCLung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756–765.
62.Shea B, Wells G, Cranney A, et al.; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002;23:552–559.
63.NIH Consensus Conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA 1994;272:1942–1948.
64.Whiting SJ. Safety of some calcium supplements questioned. Nutr Rev 1994;52:95–97.
65.Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670–676.
66.Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med1998;339:292–299.
67.Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44: 202–211.
68.Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum1999;42:2309–2318.
69.Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000;15:1006–1013.
70.Mok CC, Tong KH, To CH, et al. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. Osteoporos Int2008;19:357–364.
71.Reid DM, Devogelaer JP, Saag K, et al.; HORIZON Investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009;373:1253–1263.
72.Montemurro L, Schiraldi G, Fraioli P, et al. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991;49:71–76.
73.Luengo M, Pons F, Martinez de Osaba MJ, et al. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study., Thorax1994;49:1099–1102.
74.Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028–2039.
75.Anderson FH, Francis RM, Faulkner K. Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone1996;18:171–177.
76.Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab1996;81:4358–4365.
77.Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82:2386–2390.
78.Sawka AM, Papaioannou A, Adachi JD, et al. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 2005;6:39.
79.Ringe JD, Faber H, Farahmand P, et al. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006;26: 427–431.
80.Ringe JD, Farahmand P, Faber H, et al. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int 2009;29:311–315.
81.Boonen S, Orwoll ES, Wenderoth D, et al. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 2009;24:719–725.
82.Majima T, Shimatsu A, Komatsu Y, et al. Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study. J Bone Miner Metab 2009;27:168–174.
83.Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab2000;85:3069–3076.
84.Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9–17.
85.Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216–1226.
86.Parker MJ, Gillespie WJ, Gillespie LD. Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev 2005;(3):CD001255.
87.Sawka AM, Boulos P, Beattie K, et al. Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int2005;16:1461–1474.
88.Nelson HD. Menopause. Lancet 2008;371:760–770.
89.Bäckström T. Symptoms related to the menopause and sex steroid treatments. Ciba Found Symp 1995;191:171–186.
90.Maclennan AH, Broadbent JL, Lester S, et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;(4):CD002978.
91.American College of Obstetricians and Gynecologists Women’s Health Care Physicians. Vasomotor symptoms. Obstet Gynecol 2004;104(4 Suppl):106S–117S.
92.Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–613.
93.North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause2007;14:168–182.
94.ACOG Task Force for Hormone Therapy American College of Obstetricians and Gynecologists Women’s Health Care Physicians. Summary of balancing risks and benefits. Obstet Gynecol 2004;104(4 suppl):128S–129S.
95.American College of Obstetricians and Gynecologists Women’s Health Care Physicians. Ovarian, endometrial, and colorectal cancers. Obstet Gynecol 2004;104 (4 suppl):77S–84S.
96.Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057–2071.
97.Toulis KA, Tzellos T, Kouvelas D, et al. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. Clin Ther2009;31:221–235.
98.Lethaby AE, Brown J, Marjoribanks J, et al. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007;(4):CD001395.
99.Krebs EE, Ensrud KE, MacDonald R, et al. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004;104:824–836.
100.American College of Obstetricians and Gynecologists Women’s Health Care Physicians. Genitourinary tract changes. Obstet Gynecol 2004;104(4 Suppl):56S–61S.
101.Spitzer M. Cervical screening adjuncts: recent advances. Am J Obstet Gynecol 1998;179:544–556.
102.Screening for cervical cancer. Practice Bulletin No. 131. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;131:1222–1238.
103.International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervis: collaborative reanalysis of individual data on 8097 women with squamous cell carcinoma and 1374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 2006;120:885–891.
104.Saslow D, Solomon D, Loawson HW et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cander J Clin 2012;62:147-172.
105.Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. U.S. Preventive Services Task Force. Ann Intern Med 2012;156:880–891.
106.Wright TC Jr, Massad LS, Dunton CJ, et al.; 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197:346–355.
107.Huang W, Molitch ME. Evaluation and management of galactorrhea. Am Fam Phys 2012;85(11):1074–1080.
108.Hussain AN, Policarpio C, Vincent MT. Evaluating nipple discharge. Obstet Gynecol Surv 2006;61:278–283.
109.Gray RJ, Pockaj BA, Karstaedt, PJ. Navigating murkey waters: a modern treatment algorithm for nipple discharge. Am J of Surg 2007;194:850–855.
110.Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010;59:56–63.
111.Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev 2009;(3):CD006055.
112.Senok AC, Verstraelen H, Temmerman M, et al. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev 2009;(4):CD006289.
113.Forna F, Gülmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev 2003;(2):CD000218.
114.Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004;351:876–883.
115.Bonaiuti D, Shea B, Iovine R, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2002;(3):CD000333.